Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

BACKGROUND: Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. METHODS: In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to ≥1 convention...

Descripción completa

Detalles Bibliográficos
Autores principales: Dougados, Maxime, van der Heijde, Désirée, Chen, Ying-Chou, Greenwald, Maria, Drescher, Edit, Liu, Jiajun, Beattie, Scott, Witt, Sarah, de la Torre, Inmaculada, Gaich, Carol, Rooney, Terence, Schlichting, Douglas, de Bono, Stephanie, Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264214/
https://www.ncbi.nlm.nih.gov/pubmed/27689735
http://dx.doi.org/10.1136/annrheumdis-2016-210094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264214/
https://www.ncbi.nlm.nih.gov/pubmed/27689735
http://dx.doi.org/10.1136/annrheumdis-2016-210094

Ejemplares similares